Your browser is no longer supported. Please, upgrade your browser.
Settings
IMGN ImmunoGen, Inc. daily Stock Chart
IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own0.90% Shs Outstand147.22M Perf Week-0.35%
Market Cap831.79M Forward P/E- EPS next Y-1.33 Insider Trans1.17% Shs Float146.68M Perf Month13.23%
Income-167.90M PEG- EPS next Q-0.24 Inst Own85.30% Short Float9.89% Perf Quarter1.25%
Sales53.80M P/S15.46 EPS this Y-8.10% Inst Trans-0.11% Short Ratio5.47 Perf Half Y-36.23%
Book/sh0.32 P/B17.66 EPS next Y5.00% ROA-46.90% Target Price14.38 Perf Year-44.33%
Cash/sh2.06 P/C2.74 EPS next 5Y- ROE-733.00% 52W Range3.80 - 13.41 Perf YTD17.71%
Dividend- P/FCF- EPS past 5Y-2.50% ROI371.00% 52W High-57.87% Beta2.35
Dividend %- Quick Ratio4.60 Sales past 5Y26.60% Gross Margin- 52W Low48.68% ATR0.37
Employees293 Current Ratio4.60 Sales Q/Q28.20% Oper. Margin- RSI (14)56.81 Volatility6.38% 6.90%
OptionableYes Debt/Eq0.04 EPS Q/Q47.80% Profit Margin- Rel Volume0.75 Prev Close5.49
ShortableYes LT Debt/Eq0.04 EarningsFeb 08 BMO Payout- Avg Volume2.65M Price5.65
Recom- SMA209.68% SMA5010.98% SMA200-29.63% Volume2,000,391 Change2.91%
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Feb-01-16Reiterated RBC Capital Mkts Outperform $19 → $18
Nov-25-15Upgrade Jefferies Hold → Buy
Sep-21-15Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-03-15Downgrade Cantor Fitzgerald Buy → Hold
Jul-29-15Reiterated Oppenheimer Outperform $13 → $24
Jul-27-15Reiterated RBC Capital Mkts Outperform $15 → $20
Jun-08-15Reiterated Leerink Partners Mkt Perform $9 → $15
Jun-01-15Upgrade Morgan Stanley Underweight → Equal-Weight
Jun-01-15Reiterated Canaccord Genuity Buy $15 → $20
Apr-27-15Reiterated Canaccord Genuity Buy $10 → $15
Mar-31-15Reiterated UBS Neutral $7 → $9
Feb-06-15Upgrade Oppenheimer Perform → Outperform $11
Dec-22-14Reiterated RBC Capital Mkts Outperform $18 → $11
Jun-12-14Upgrade UBS Sell → Neutral $8.50 → $13
Feb-18-19 02:19PM  How ImmunoGen, Inc. (NASDAQ:IMGN) Could Add Value To Your Portfolio Simply Wall St.
Feb-12-19 07:15PM  Edited Transcript of IMGN earnings conference call or presentation 8-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -7.43%
03:58PM  ImmunoGen Still Waiting to Take Its Leap "Forward" Motley Fool
Feb-11-19 09:29AM  ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up Zacks
08:53AM  Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock Zacks
Feb-08-19 09:35PM  ImmunoGen (IMGN) Q4 2018 Earnings Conference Call Transcript Motley Fool +10.31%
07:45AM  ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:47AM  ImmunoGen: 4Q Earnings Snapshot Associated Press
06:30AM  ImmunoGen Reports Recent Progress and 2018 Operating Results Business Wire
Feb-06-19 06:35PM  Why ImmunoGen Jumped Almost 14% Today Motley Fool +13.66%
Feb-01-19 10:30AM  Earnings Preview: ImmunoGen (IMGN) Q4 Earnings Expected to Decline Zacks
Jan-24-19 04:30PM  ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results Business Wire
Jan-18-19 03:00PM  Have Insiders Been Selling ImmunoGen, Inc. (NASDAQ:IMGN) Shares This Year? Simply Wall St.
Jan-09-19 07:39AM  The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-08-19 04:01PM  ImmunoGen Announces Sale of Residual Kadcyla Royalties Business Wire
Jan-07-19 05:20PM  Why ImmunoGen Jumped Today Motley Fool +10.53%
Jan-02-19 08:30AM  ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-26-18 04:18PM  Why ImmunoGen Shot Up 13% Today Motley Fool +13.07%
Dec-17-18 09:52PM  Hedge Funds Are Betting On ImmunoGen, Inc. (IMGN) Insider Monkey
Dec-12-18 07:55AM  Market Trends Toward New Normal in Marriott International, Duke Energy, ImmunoGen, Newell Brands, Vail Resorts, and Fiserv Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-06-18 02:49PM  Roche's Kadcyla Halves Death Risk in Breast Cancer Study Zacks
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
09:30AM  ImmunoGen (IMGN) Down 7.2% Since Last Earnings Report: Can It Rebound? Zacks
Dec-01-18 10:31AM  ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting Business Wire
Nov-27-18 07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga -8.20%
Nov-26-18 04:47PM  Former Aveo exec resigns as ImmunoGen CFO after fraud verdict American City Business Journals
04:01PM  ImmunoGen Announces Resignation of Chief Financial Officer Business Wire
Nov-25-18 09:41AM  The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings Benzinga
Nov-21-18 11:23AM  Former Aveo CFO misled biotech's investors, jury finds American City Business Journals
Nov-20-18 08:31AM  Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock? Zacks
Nov-19-18 07:31AM  Edited Transcript of IMGN earnings conference call or presentation 2-Nov-18 12:00pm GMT Thomson Reuters StreetEvents -7.36%
Nov-14-18 11:35AM  Healthcare Stocks with Turnaround Potential ACCESSWIRE
Nov-09-18 02:12PM  ImmunoGen Waits to Leap "Forward" Motley Fool
Nov-07-18 08:28PM  Here's Why ImmunoGen Closed Almost 12% Up on Wednesday Motley Fool +11.98%
09:46AM  Here's Why ImmunoGen Shares Lost 42.7% in October Motley Fool
08:20AM  Report: Developing Opportunities within TE Connectivity, EnPro Industries, Innophos, Ameren, ImmunoGen, and ICF International Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-06-18 04:30PM  ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire
Nov-05-18 11:01AM  How ImmunoGen Inc (NASDAQ:IMGN) Can Impact Your Portfolio Volatility Simply Wall St.
09:35AM  ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance Zacks
Nov-02-18 12:12PM  Immunogen Inc (IMGN) Q3 2018 Earnings Conference Call Transcript Motley Fool
10:43AM  MARKETS: Today's job numbers might have been too good and could spook stocks Yahoo Finance Video
09:40AM  ImmunoGen (IMGN) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:36AM  ImmunoGen: 3Q Earnings Snapshot Associated Press
06:30AM  ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results Business Wire
Nov-01-18 02:55PM  Q3 Earnings Outlook For ImmunoGen Benzinga +9.39%
09:01AM  ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting Business Wire
Oct-26-18 10:30AM  ImmunoGen (IMGN) Q3 Earnings Preview: What to Look Out For Zacks
Oct-22-18 11:05AM  Here's Why ImmunoGen Fell Today Motley Fool -16.02%
Oct-20-18 06:30AM  ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress Business Wire
Oct-18-18 04:30PM  ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results Business Wire
Oct-15-18 10:30AM  Cancer Companies to Watch ACCESSWIRE
Oct-14-18 01:21PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-10-18 08:30AM  Report: Developing Opportunities within Southwest Airlines, Select Income REIT, Oxford Industries, ImmunoGen, Navigant Consulting, and TrueBlue Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-08-18 06:05PM  ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO Business Wire
09:50AM  Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock? Zacks
Oct-05-18 05:00PM  Why ImmunoGen Inc. Dropped 8% Today Motley Fool -9.00%
Oct-04-18 05:53PM  Why ImmunoGen, Inc. Fell 10.6% on Thursday Motley Fool -10.62%
Sep-24-18 04:30PM  ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire
Sep-19-18 08:31AM  Who Owns Most Of ImmunoGen Inc (NASDAQ:IMGN)? Simply Wall St.
Aug-27-18 04:30PM  ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire +6.60%
Aug-06-18 07:45AM  Investor Expectations to Drive Momentum within Ingevity, First Industrial Realty Trust, ImmunoGen, PriceSmart, Pacific Gas & Electric, and Procter & Gamble Discovering Underlying Factors of Influence GlobeNewswire
Jul-31-18 04:30PM  ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference Business Wire
04:06PM  ImmunoGen's Investors Play the Waiting Game Motley Fool
Jul-30-18 11:09AM  Edited Transcript of IMGN earnings conference call or presentation 27-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
10:16AM  ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates Zacks
Jul-27-18 07:50AM  ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates Zacks
06:58AM  ImmunoGen (IMGN) Q2 Loss Wider, Revenues Miss Zacks
06:30AM  ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results Business Wire
06:00AM  ImmunoGen, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-18 02:59PM  Immunogen Earnings Preview Benzinga
Jul-25-18 11:28AM  What's in Store for ImmunoGen (IMGN) This Earnings Season? Zacks
Jul-13-18 02:33PM  Here's Why ImmunoGen Fell 15.1% in June Motley Fool
Jul-12-18 04:30PM  ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results Business Wire
Jun-26-18 08:05AM  Better Buy: Exelixis, Inc. vs. Immunogen, Inc. Motley Fool
Jun-22-18 07:30AM  Free Technical Research on ImmunoGen and Three More Biotech Equities ACCESSWIRE
Jun-21-18 08:15AM  ImmunoGen Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jun-19-18 09:41AM  ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer Zacks
Jun-18-18 08:00AM  ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer Business Wire
Jun-11-18 04:05PM  ImmunoGen Announces Closing of Public Offering of Common Stock Business Wire
Jun-07-18 05:33PM  Here's Why ImmunoGen Inc. Fell 9.2% Today Motley Fool -9.22%
Jun-06-18 08:59PM  ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock Business Wire
08:38AM  Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate Benzinga
08:34AM  Has ImmunoGen Inc (NASDAQ:IMGN) Improved Earnings Growth In Recent Times? Simply Wall St.
Jun-05-18 04:59PM  Immunogen shares down 4% after company's plans for secondary offering MarketWatch +7.40%
04:03PM  ImmunoGen Announces Proposed Public Offering of Common Stock Business Wire
Jun-04-18 05:18AM  Why Is ImmunoGen (IMGN) Up 4.2% Since Its Last Earnings Report? Zacks -7.37%
May-31-18 03:31PM  Why ImmunoGen Jumped Higher Today Motley Fool +9.46%
May-30-18 04:15PM  ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference Business Wire
May-16-18 05:01PM  ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer Business Wire
May-09-18 04:02AM  Edited Transcript of IMGN earnings conference call or presentation 4-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-08-18 07:34PM  ImmunoGen Presses Forward Motley Fool
May-07-18 09:12AM  ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat Zacks
May-04-18 07:18AM  ImmunoGen (IMGN) Q1 Loss Wider, Revenues Beat Zacks
06:40AM  ImmunoGen: 1Q Earnings Snapshot Associated Press
06:30AM  ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results Business Wire
06:00AM  ImmunoGen, Inc. to Host Earnings Call ACCESSWIRE
May-02-18 04:30PM  ImmunoGen Announces Webcast of Presentation at Deutsche Banks 43rd Annual Health Care Conference Business Wire
Apr-30-18 11:27AM  What's in Store for ImmunoGen (IMGN) This Earnings Season? Zacks
Apr-27-18 01:04PM  Why ImmunoGen, Inc. Stock Is on the Rise Today Motley Fool
06:54AM  Heres Why The Immunogen News Is Important For The Company Market Exclusive
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gregory Richard J.Executive VP & CSOJan 07Sale5.273,03816,014236,056Jan 08 08:47 AM
Goldberg Mark AlanDirectorNov 06Buy5.7630,000172,80053,800Nov 07 09:54 AM
Berkenblit AnnaVP & Chief Medical OfficerOct 16Sale8.005,85146,808132,769Oct 17 09:51 AM
Berkenblit AnnaVP & Chief Medical OfficerSep 10Sale9.465,85155,350138,620Sep 11 05:20 PM
Johnston David BrannonChief Financial OfficerJun 06Option Exercise3.0510,00030,500190,690Jun 08 04:08 PM
Johnston David BrannonChief Financial OfficerJun 06Sale11.0210,000110,200180,690Jun 08 04:08 PM
JUNIUS DANIEL MDirectorMar 16Option Exercise4.2925,000107,250209,987Mar 16 05:12 PM
JUNIUS DANIEL MDirectorMar 16Sale12.0225,000300,405184,987Mar 16 05:12 PM
Johnston David BrannonChief Financial OfficerMar 15Option Exercise3.0510,00030,500190,690Mar 16 09:21 AM
Johnston David BrannonChief Financial OfficerMar 15Sale11.5310,000115,300180,690Mar 16 09:21 AM
JUNIUS DANIEL MDirectorFeb 21Sale12.0011,713140,556184,987Feb 23 10:29 AM
Enyedy Mark JChief Executive OfficerFeb 21Sale10.8767,717736,084532,383Feb 23 11:46 AM
Berkenblit AnnaVP & Chief Medical OfficerFeb 21Sale10.8817,329188,540144,471Feb 23 11:45 AM
Johnston David BrannonChief Financial OfficerFeb 21Sale10.8721,060228,922180,690Feb 23 11:45 AM
Wingrove TheresaVP of Regulatory AffairsFeb 21Sale10.8811,379123,80490,671Feb 23 11:46 AM
Ryll ThomasVP, Technical OperationsFeb 21Sale10.8811,876129,21196,224Feb 23 11:46 AM
Gregory Richard J.Executive VP & CSOFeb 21Sale10.8834,486375,208239,094Feb 23 11:45 AM
BARROWS CRAIGExecutive VP, General CounselFeb 21Sale10.8815,498168,618168,952Feb 23 11:45 AM
JUNIUS DANIEL MDirectorFeb 20Sale11.6825,000292,000196,700Feb 21 08:47 AM